NIP
ELVN icon

Nicholas Investment Partners’s Enliven Therapeutics ELVN Stock Holding History

Nicholas Investment Partners’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9M Buy
391,529
+208,801
+114% +$8.86M 1.12% 21
2026
Q1 		$7.16M Buy
+182,728
New +$5.06M 0.52% 72
2025
Q1 		– Sell
-157,635
Closed -$3.55M – 208
2024
Q4 		$3.55M Sell
157,635
-16,110
-9% -$418K 0.31% 116
2024
Q3 		$4.44M Buy
173,745
+117,673
+210% +$2.73M 0.41% 93
2024
Q2 		$1.31M Buy
+56,072
New +$1.18M 0.14% 158

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Nicholas Investment Partners's ELVN Position: Q2 2026 in Review

Nicholas Investment Partners increased its Enliven Therapeutics (ELVN) stake by 114% in Q2 2026, buying an estimated $8.86M and bringing the position to 391,529 shares worth $19.9M. The position accounts for 1.12% of the portfolio, ranked #21.

Nicholas Investment Partners first reported a position in ELVN in Q2 2024 and has held it in 5 quarters since. 213 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Nicholas Investment Partners held 391,529 shares of Enliven Therapeutics worth $19.9M as of Q2 2026.
  • Nicholas Investment Partners bought 208,801 Enliven Therapeutics shares in Q2 2026, an estimated $8.86M.
  • Enliven Therapeutics made up 1.12% of Nicholas Investment Partners's portfolio in Q2 2026, its #21 holding.
  • Nicholas Investment Partners first reported a position in Enliven Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 213 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.